The emerging role of glucagon-like peptide-1 receptor agonists in male infertility: mechanisms, experimental evidence, and future clinical perspectives
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262889Keywords:
Male infertility, GLP-1RAs, Obesity, Reproductive health, Spermatogenesis, Testosterone, Semen quality, Functional hypogonadism, Liraglutide, SemaglutideAbstract
Obesity and metabolic dysfunction are major modifiable risk factors for male infertility, affecting reproductive function via insulin resistance, oxidative stress, chronic inflammation, hypothalamic-pituitary-gonadal axis dysregulation and impaired steroidogenesis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used to treat obesity and type 2 diabetes mellitus and have emerged as potential modulators of male reproductive health, due to their metabolic effects and potential direct effects on reproductive tissues. This narrative review aimed to assess the current evidence regarding the potential role of GLP-1RAs in obesity-related male infertility, including underlying mechanisms, experimental findings, clinical evidence, and future therapeutic implications. A narrative literature search was conducted in PubMed, Scopus, Google Scholar, and Web of Science for relevant publications from 2018 to 2025, including original research, clinical trials, observational studies, experimental studies, systematic reviews, and relevant guidelines on GLP-1RAs, male reproductive physiology, semen parameters, reproductive hormones, and obesity-associated infertility. Evidence suggests that GLP-1RAs may influence male reproductive function via both indirect and direct effects on reproductive tissues. Experimental studies have shown expression of the GLP-1 receptor in reproductive cells including Leydig cells, Sertoli cells and spermatozoa, suggesting potential roles in steroidogenesis, cellular metabolism, mitochondrial function and spermatogenesis. In addition, the relative contribution of direct pharmacological effects compared to metabolic improvement by weight loss remains unclear. Overall, GLP-1RAs appear to be a promising therapeutic approach for treating obesity-related male reproductive dysfunction by acting on both metabolic health and possibly restoring reproductive function. However, there is not enough evidence at present to justify the recommendation of GLP-1RAs as established fertility-enhancing agents. To determine their role in the evidence-based management of male infertility, large, adequately powered randomised controlled trials evaluating semen quality, sperm DNA integrity, reproductive hormone profiles, pregnancy, and long-term safety are required.
References
Varnum AA, Pozzi E, Deebel NA, Evans A, Eid N, Sadeghi-Nejad H, et al. Impact of GLP-1 agonists on male reproductive health—a narrative review. Medicina (Kaunas). 2024;60(1):50.
Telek SB. Relevance of GLP-1 agonists for infertility practice. Reprod Biomed Online. 2024;49:104522.
Cannarella R, Calogero AE, Condorelli RA, Greco E, Aversa A, La Vignera S. Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility? Andrology. 2021;9(5):1499-503.
du Plessis SS, Omolaoye TS, Cardona Maya WD. Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution. Front Physiol. 2024;15:1496416.
Goldberg AC, Boots CE. Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists. Fertil Steril. 2024;122(2):211-8.
Salonia A, Capogrosso P, Boeri L, Cocci A, Corona G, Dinkelman-Smit M, et al. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease. Eur Urol. 2025;88(1):76-102.
Hammad B, Zafar N, Ullah M, Faisal S, Iftikhar F, Waheed H, et al. Exploring the multifaceted roles of GLP-1 receptor agonists: a comprehensive review. Front Clin Diabetes Healthc. 2025;6:1590530.
American Diabetes Association. Standards of care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1).
Abedi M, Patni M, Shajahan A, Dube R, Khadeeja L, Alabid I, et al. GLP-1 receptor agonists, fertility restoration, and reproductive safety in women of reproductive age: a narrative review. J Clin Med. 2026;15(9):3204.
Andersen E, Juhl CR, Kjøller ED, Lundgren J, Janus C, Dehestani Y, et al. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Hum Reprod. 2022;37(7):1414-22.
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.
Varnum AA, Pozzi E, Deebel NA, Evans A, Eid N, Sadeghi-Nejad H, et al. Impact of GLP-1 agonists on male reproductive health—a narrative review. Medicina (Kaunas). 2024;60(1):50.
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.
Willard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
Genchi VA, Rossi E, Lauriola C, D'Oria R, Palma G, Borrelli A, et al. Adipose tissue dysfunction and obesity-related male hypogonadism. Int J Mol Sci. 2022;23(15):8194.
Kuchakulla M, Poppas PJ, Wald G, Masterson JM, Gurayah AA, Bhambhvani HP, et al. Impact of GLP-1 receptor agonists on male fertility: emerging evidence and future directions. Urology. 2025;213:9-17.
La Vignera S, Condorelli RA, Calogero AE, Cannarella R, Aversa A. Sexual and reproductive outcomes in obese fertile men with functional hypogonadism after treatment with liraglutide: preliminary results. J Clin Med. 2023;12(2):672.
Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabbà C, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015;3(6):1094-03.
Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8(3):195-202.
Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;385(11):989-1002.
Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone is a contraceptive and should not be used in men who desire fertility. World J Mens Health. 2019;37(1):45-54.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-16.
Samavat J, Cantini G, Lotti F, Di Franco A, Tamburrino L, Degl'Innocenti S, et al. Massive weight loss obtained by bariatric surgery affects semen quality in morbid male obesity: a preliminary prospective double-armed study. Obes Surg. 2018;28(1):69-76.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-50.
Caltabiano R, Condorelli D, Panza S, Boitani C, Musso N, Ježek D, et al. Glucagon-like peptide-1 receptor is expressed in human and rodent testis. Andrology. 2020;8(6):1935-45.
Rago V, De Rose D, Santoro M, Panza S, Malivindi R, Andò S, et al. Human sperm express the receptor for glucagon-like peptide-1 (GLP-1), which affects sperm function and metabolism. Endocrinology. 2020;161(4):bqaa031.
Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(5):504-17.
Lengsfeld S, Probst L, Emara Y, Werlen L, Vogt DR, Bathelt C, et al. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. Biomedicine. 2024;107:105284.
Martins AD, Monteiro MP, Silva BM, Barros A, Sousa M, Carvalho RA, et al. Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1. Toxicol Appl Pharmacol. 2018;362:1-8.
Downloads
Published
How to Cite
Issue
Section
